LexaGene is a molecular diagnostics company that has commercialized the MiQLab System for fast and easy detection of biological contaminants, pathogens and other molecular markers. The System is designed for on-site usage and uses real-time PCR chemistry. Our customers include biopharmaceutical companies and veterinary hospitals. The MiQLab System delivers excellent sensitivity, specificity, and breadth of detection.
Company profile
Ticker
LXXGQ, LXXGF
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
STONESHIELD CAPITAL CORP, STONESHIELD CAPITAL CORP.
SEC CIK
Latest filings (excl ownership)
8-K
Bankruptcy or Receivership
24 Feb 23
S-8
Registration of securities for employees
9 Feb 23
8-K
Submission of Matters to a Vote of Security Holders
8 Feb 23
8-K
LexaGene Provides Update on BioPharma Sector
8 Feb 23
8-K
Regulation FD Disclosure
18 Jan 23
10-Q
2023 Q3
Quarterly report
17 Jan 23
DEFA14A
Additional proxy soliciting materials
30 Dec 22
DEF 14A
Definitive proxy
30 Dec 22
8-K
BioPharma Engages LexaGene in Second Feasibility Study
16 Dec 22
8-K
Regulation FD Disclosure
7 Dec 22
Latest ownership filings
No filings
Financial summary
Quarter (USD) | Nov 22 | Aug 22 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Cash on hand (at last report) | 464.13 k | 464.13 k | 464.13 k | |||
Cash burn (monthly) | 208.43 k | 557.56 k | (no burn) | |||
Cash used (since last report) | 3.51 mm | 9.40 mm | n/a | |||
Cash remaining | -3.05 mm | -8.93 mm | n/a | |||
Runway (months of cash) | -14.6 | -16.0 | n/a |